Jaguar Health, Inc. JAGX
Jaguar Health, Inc. ("Jaguar"), in conjunction with Jaguar family company Napo Pharmaceuticals, Inc. ("Napo"), develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo and Napo Therapeutics, S.p.A., an Italian corporation Jaguar was established in Milan, Italy in 2021, are focused on expanding global crofelemer access and are developing new therapies for orphan and rare GI conditions. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., is focused on developing novel prescription medicines derived from plants for mental health indications.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M | $5.8M | $4.4M | $4.4M | $141.5K |
| Cost of revenue | $3.8M | $2.0M | $2.0M | $2.0M | $2.3M | $3.3M | $3.8M | $2.8M | $880.4K | $52.0K |
| Gross profit | $7.7M | $9.7M | $7.7M | $9.9M | $2.0M | $6.1M | $2.0M | $1.7M | $3.5M | $89.6K |
| R&D | $25.0M | $16.5M | $18.6M | $17.6M | $15.1M | $6.4M | $5.8M | $5.2M | $4.3M | $7.2M |
| SG&A | $18.6M | $16.3M | $16.6M | $17.9M | $17.1M | $14.4M | $13.5M | $12.3M | $11.2M | $6.0M |
| Total operating expenses | $57.4M | $42.5M | $44.1M | $46.4M | $45.0M | $36.0M | $34.7M | $35.2M | $38.6M | $13.7M |
| Operating income | -$45.9M | -$30.8M | -$34.3M | -$34.4M | -$40.7M | -$26.6M | -$28.9M | -$30.8M | -$34.2M | -$13.6M |
| Interest expense | $67.0K | $231.0K | $6.4M | $12.7M | $8.4M | $2.8M | $5.7M | $2.6M | $1.2M | $985.5K |
| Pre-tax income | -$54.0M | -$39.3M | -$41.9M | -$48.4M | -$52.6M | -$33.8M | -$38.5M | -$32.1M | -$35.1M | -$14.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $10.0K | — | $13.2M | — |
| Net income | -$54.0K | -$39.2K | -$41.9K | -$48.4K | -$52.6K | -$33.8M | -$38.5M | -$32.1M | -$22.0M | -$14.7M |
| EPS, basic | -22.97 | -130.69 | -2,678.17 | -36.18 | -88.22 | -3.00 | — | — | — | — |
| EPS, diluted | -22.97 | -130.69 | -2,678.17 | -36.18 | -88.22 | -3.00 | -9.01 | -153.27 | -7.59 | -1.35 |
| Shares, diluted (wtd. avg.) | $2.3M | $294.5K | $15.4K | $1.3M | $596.2K | $12.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $968.0K | $8.0M | $6.5M | $5.5M | $17.1M | $8.1M | $3.9M | $2.6M | $759.9K | $1.5M |
| Receivables | $1.5M | $1.5M | $2.0M | $1.9M | $1.7M | $2.1M | $1.7M | $995.7K | $467.7K | $5.0K |
| Inventory | $8.6M | $10.3M | $9.2M | $7.0M | $4.9M | $2.8M | $2.1M | $3.3M | $2.1M | $412.8K |
| Total current assets | $20.3M | $32.2M | $28.0M | $22.3M | $28.4M | $17.8M | $9.5M | $8.1M | $3.8M | $2.6M |
| Property, plant and equipment | $463.0K | $464.0K | $496.0K | $557.0K | $650.0K | $677.0K | $710.0K | $760.6K | $1.2M | $885.9K |
| Goodwill | — | — | — | — | — | — | — | $5.2M | $5.2M | — |
| Other intangibles | $16.0M | $18.5M | $20.1M | $22.4M | $22.7M | $24.3M | $26.0M | $31.7M | $33.4M | — |
| Total assets | $38.3M | $53.4M | $50.8M | $47.5M | $53.3M | $42.8M | $36.4M | $41.0M | $43.6M | $3.6M |
| Accounts payable | $8.7M | $5.3M | $5.0M | $5.8M | $4.9M | $4.8M | $5.4M | $5.4M | $7.4M | $517.0K |
| Short-term debt | — | — | — | — | — | — | — | — | $1.6M | $1.9M |
| Total current liabilities | $40.7M | $19.7M | $14.0M | $30.3M | $15.5M | $13.2M | $15.4M | $26.7M | $15.4M | $4.2M |
| Long-term debt | — | — | — | — | — | — | — | — | — | $1.8M |
| Total liabilities | $57.0M | $44.4M | $45.9M | $48.8M | $41.4M | $25.6M | $15.8M | $26.7M | $26.4M | $6.0M |
| Retained earnings | -$399.9M | -$346.5M | -$308.2M | -$266.9M | -$219.5M | -$166.9M | -$133.1M | -$94.6M | -$62.4M | -$40.4M |
| Total equity | -$18.7M | $6.5M | $4.9M | -$1.4M | $11.9M | $17.2M | $10.7M | $5.4M | $17.3M | -$2.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.7M | -$29.4M | -$33.2M | -$33.1M | -$35.0M | -$15.3M | -$20.5M | -$22.7M | -$9.8M | -$14.4M |
| Depreciation and amortisation | $1.9M | $1.9M | $2.0M | $2.0M | $1.7M | $1.7M | $1.7M | $1.3M | $584.3K | $47.5K |
| Stock-based compensation | $831.0K | $1.6M | $2.1M | $3.3M | $4.0M | $2.8M | $3.0M | $2.0M | $814.6K | $717.9K |
| Capital expenditure | — | $16.0K | — | $77.0K | $6.0K | $7.0K | — | $6.5K | — | $104.2K |
| Investing cash flow | -$41.0K | -$231.0K | — | -$1.7M | -$6.0K | -$7.0K | — | -$6.5K | -$1.6M | $2.4M |
| Financing cash flow | $23.7M | $31.2M | $34.2M | $23.2M | $43.9M | $19.5M | $21.8M | $24.5M | $10.7M | $5.3M |
| Buybacks | — | — | — | — | — | — | — | $30 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-192753.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |